OpenClinica has completed a growth recapitalization with Thompson Street Capital Partners to accelerate the enablement of clinical trials.
Continued decentralization, a stringent regulatory environment requiring increased compliance and patient outcome visibility, and a constantly growing number of disparate data sources (including RWD and RWE) in clinical trials have bolstered the need for easier and more secure data sharing between researchers and the practitioners administering these trials. As a result, demand for easy to use, unified electronic data capture (EDC) platforms to ensure data reliability and facilitate secure sharing continues to grow.
As an industry-leading clinical research solutions provider, OpenClinica empowers sponsors, CROs, and academics with its automated, fully featured EDC complete with an innovative toolset and dynamic, comprehensive eCRFs for clinical trials, enabling researchers to collect data faster, more accurately, and at a lower cost. These differentiators made OpenClinica an ideal target for a strategic growth investment from Thompson Street Capital Partners given their focus on life science, healthcare, and software companies.
Crosstree acted as exclusive financial advisor to OpenClinica in its growth recapitalization with Thompson Street through:
- Helping the client develop a sell-side Quality of Earnings in a tight market with tight timelines
- Developing and articulating a strong value proposition that connected client capabilities with market trends to weave a compelling narrative for potential buyers
- Assessing multiple competitive offers received from a narrow group of hand-picked potential buyers so buyer could base decision on real data, not hypothesis
- Moving through an accelerated process from IOI to LOI and closed in 45 days after LOI